New malaria pill shows promise in large trial

NCT ID NCT05842954

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new malaria drug called KLU156 in over 1,700 adults and children with uncomplicated malaria. It compared KLU156 to a standard treatment, Coartem, to see if it works as well. Some participants continued taking KLU156 for up to two years to check its safety with repeated use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KLU156 (ganaplacide and lumefantrine combination)
What this could lead to: If successful, KLU156 could offer a new, once-daily, 3-day treatment option for uncomplicated malaria, potentially effective against drug-resistant strains.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The extension phase only includes patients who responded well initially, so long-term safety in all patients is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA

Contacts and locations

Locations

Novartis Investigative Site

Banfora, Burkina Faso
Novartis Investigative Site

Bobo-Dioulasso, 01, Burkina Faso
Novartis Investigative Site

Nanoro, BP 18, Burkina Faso
Novartis Investigative Site

Ouagadougou, 11 BP 218, Burkina Faso
Novartis Investigative Site

Sabou, 06 BP 10248, Burkina Faso
Novartis Investigative Site

Abidjan, 13BP972, Côte d’Ivoire
Novartis Investigative Site

Agboville, BP 154, Côte d’Ivoire
Novartis Investigative Site

Azaguié, BP 173, Côte d’Ivoire
Novartis Investigative Site

Kimpese, Bas-Congo Province, Democratic Republic of the Congo
Novartis Investigative Site

Kisantu, Bas-Congo Province, Democratic Republic of the Congo
Novartis Investigative Site

Lubumbashi, Du Haut Katanga, 7010, Democratic Republic of the Congo
Novartis Investigative Site

Kenge, Kwango, Democratic Republic of the Congo
Novartis Investigative Site

Masi-Manimba, Kwilu, Democratic Republic of the Congo
Novartis Investigative Site

Lambaréné, BP 242, Gabon
Novartis Investigative Site

Libreville, BP 1437, Gabon
Novartis Investigative Site

Kintampo, 92037, Ghana
Novartis Investigative Site

Navrango, VWJ6+8WF, Ghana
Novartis Investigative Site

Kombewa, 40102, Kenya
Novartis Investigative Site

Nairobi, 00200, Kenya
Novartis Investigative Site

Siaya, 2300, Kenya
Novartis Investigative Site

Sotouba, Mali
Novartis Investigative Site

Niamey, 8003, Niger
Novartis Investigative Site

Gicumbi, Northern Province, 00114, Rwanda
Novartis Investigative Site

Kigali, 0000, Rwanda
Novartis Investigative Site

Kigali, BP 4560, Rwanda
Novartis Investigative Site

Rubavu, Rwanda
Novartis Investigative Site

Rusizi, Rwanda
Novartis Investigative Site

Bagamoyo, Tanzania
Novartis Investigative Site

Korogwe Tanga, Tanzania
Novartis Investigative Site

Tanga, 5004, Tanzania
Novartis Investigative Site

Tororo, 10102, Uganda
Novartis Investigative Site

Nchelenge, Luapula Province, 70100, Zambia
Novartis Investigative Site

Ndola, 71769, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.